| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Health Care sector is very positive (overall 4.8, positive 5, negative -0.2) on 20251121. The forces of Sentiment towards Fundamentals (2.7), Valuation Sentiment (2.7), Price Level (2), Option Speculation (1.5), Sector Price Trend (1), and Broad Market Trend (-0.3) will drive up the price. The forces of and Market Risk Prefrence (0) will drive down the price. 'Buy the dips' is the preferred trading strategy. Hourly SMA 20 trend line is likely to provide a support from any pullbacks. The swing to upside will be significant considering the high positive sentiment forces (5). The extreme bullish overall sentiment (4.8) may signal the top of this uptrend. The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Market Sentiment | Trend Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-21 | 3% | 1.6% | 154.66 | 93 | 2.17% | 0.53% | 3.3 | 1 | 2.7 | 7.1 |
| 2025-11-20 | 2% | 1.6% | 151.38 | 75 | -0.62% | 0.4% | 2 | -0.2 | 2.3 | 6.3 |
| 2025-11-19 | 1% | 1.4% | 152.32 | 84 | -0.17% | 0.47% | 1.9 | 0.5 | 2.2 | 2.7 |
| 2025-11-18 | 2% | 1.4% | 152.58 | 90 | 0.56% | 0.47% | 2 | 1 | 1.8 | 2.3 |
| 2025-11-17 | 2% | 1.3% | 151.74 | 89 | -0.09% | 0.47% | 2.1 | 1.1 | 1.6 | 1.6 |
| 2025-11-16 | 0% | 1.1% | 2.9 | 1.5 | 2 | 5 | ||||
| 2025-11-15 | 1% | 1.1% | 3 | 1.5 | 2.1 | -6.5 | ||||
| 2025-11-14 | 3% | 1.1% | 151.87 | 96 | -0.59% | 0.54% | 2.9 | 1.5 | 2.2 | 1.2 |
| 2025-11-13 | 1% | 0.9% | 152.77 | 112 | -0.03% | 0.61% | 3.1 | 1.6 | 2.4 | -0.2 |
| 2025-11-12 | 1% | 1% | 152.81 | 126 | 1.4% | 0.55% | 3.5 | 1.6 | 2.2 | 2.2 |
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| 1 (8) Is GLP-1 the new AI? Drugmaker Eli Lilly joins the $1 trillion market-cap club. Eli Lilly on Friday crossed the $1 trillion market-cap threshold, becoming the first drugmaker to ever reach that milestone. (https://www.marketwatch.com/) Fri. Nov 21, 2025 | |
| 2 (6) This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead Healthcare stocks have outperformed the broader market by nearly 10 percentage points this month as AI bubble concerns have weighed on tech stocks. (https://www.investopedia.com/) Fri. Nov 21, 2025 | |
| 3 (10) Eli Lilly Becomes First Health-Care Company To Hit $1 Tln Market Value Eli Lilly made headlines on Friday by briefly becoming the first healthcare company in the world to hit a $1 trillion market value.. (https://www.rttnews.com/) Fri. Nov 21, 2025 | |
| 4 (7) Align Technology Inc. stock outperforms competitors on strong trading day Shares of Align Technology Inc. ALGN rallied 7.34% to $142.56 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.98% to 6,602.99 and the Dow Jones Industrial Average DJIA rising 1.08% to 46,245.41. Align Technology Inc. closed 42.09% short of its 52-week high of $246.19, which the company achieved on December 11th. (https://www.marketwatch.com/) Fri. Nov 21, 2025 | |
| 5 (7) Eli Lilly Stock Is Rising Today: Here's What You Need To Know Eli Lilly and Co (NYSE:LLY) shares are trading higher on Friday. The company plans to start selling its obesity drug through a new approach aimed at expanding access. (https://www.benzinga.com/) Fri. Nov 21, 2025 | |
| 6 (8) AstraZeneca to invest $2 billion as part of US manufacturing push () -AstraZeneca said on Friday it will invest $2 billion to expand its manufacturing footprint in Maryland as part of its previously announced $50 billion plan to expand manufacturing and research capabilities in the U. Global pharmaceutical companies have been ramping up investments in the United States to expand production capacity, following President Donald Trump's call for the industry to make more medicines domestically instead of importing active ingredients or finished products. (https://finance.yahoo.com/) Fri. Nov 21, 2025 | |
| 7 (8) Is GLP-1 the new AI? Drugmaker Eli Lilly joins the $1 trillion market-cap club. Eli Lilly on Friday crossed the $1 trillion market-cap threshold, the first drugmaker to ever reach that milestone. (https://www.marketwatch.com/) Fri. Nov 21, 2025 | |
| 8 (8) Dow's 775-point rally led by gains for Merck, Sherwin-Williams Co. shares The Dow Jones Industrial Average is rallying Friday afternoon with shares of Merck and Sherwin-Williams Co. leading the way for the index. The Dow Dow Jones Industrial Average was most recently trading 775 points, or 1.7%, higher, as shares of Merck Merck & Co. Inc. and Sherwin-Williams Co. Sherwin-Williams Co. have contributed around 25% of the blue-chip gauge's intraday rally. (https://www.marketwatch.com/) Fri. Nov 21, 2025 | |
| 9 (8) Merck, Home Depot share gains lead Dow's 650-point rally Powered by positive momentum for shares of Merck and Home Depot, the Dow Jones Industrial Average is rallying Friday afternoon. Shares of Merck Merck & Co. Inc. and Home Depot Home Depot Inc. have contributed to the index's intraday rally, as the Dow Dow Jones Industrial Average was most recently trading 655 points higher (1.4%). (https://www.marketwatch.com/) Fri. Nov 21, 2025 | |
| 10 (5) How Novo Nordisk Is Trying to Regain Its Weight-Loss Edge Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat diabetes, could help trim their waistlines. (https://www.bloomberg.com/) Fri. Nov 21, 2025 | |
| 11 (8) Lilly Joins $1 Trillion Club in Weight-Loss Drug Fueled Climb The world’s largest drugmaker, Eli Lilly & Co., just notched another milestone: it’s the first health-care company to cross the $1 trillion threshold as investors bet big on the drugmaker’s weight-loss medicines. (https://www.bloomberg.com/) Fri. Nov 21, 2025 | |
| 12 (7) Eli Lilly tops $1 trillion — plus, how a Fed head threw the market a lifeline The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET. (https://www.cnbc.com/) Fri. Nov 21, 2025 | |
| 13 (-4) Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst KeyBanc initiates Zoetis at Sector Weight, citing OA drug headwinds, rising competition, and limited near-term catalysts despite strong fundamentals. (https://www.benzinga.com/) Fri. Nov 21, 2025 | |
| 14 (9) Eli Lilly hits $1 trillion market value, a first for a health-care company The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and diabetes treatment Mounjaro. (https://www.cnbc.com/) Fri. Nov 21, 2025 | |
| 15 (8) Eli Lilly joins $1 trillion club as weight-loss drugs fuel growth Eli Lilly joins $1 trillion club as weight-loss drugs fuel growth (https://www.investing.com/) Fri. Nov 21, 2025 | |
| 16 (8) BJ's beats on earnings, Ross lifts outlook, Eli Lilly hits $1T Market Catalysts host Julie Hyman tracks several of Friday's top trending stock tickers, including Eli Lilly (LLY), BJ's Wholesale Club (BJ), and Ross Stores (ROST). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. (https://finance.yahoo.com/) Fri. Nov 21, 2025 | |
| 17 (8) Is GLP-1 the new AI? Drugmaker Eli Lilly briefly joins the $1 trillion market-cap club. Eli Lilly on Friday briefly crossed the $1 trillion market-cap threshold, the first drugmaker to ever reach that milestone. (https://www.marketwatch.com/) Fri. Nov 21, 2025 | |
| 18 (8) Buy this digital health stock that's 'too compelling to ignore', says Raymond James The bank upgraded the digital platform for medical professionals to a strong buy from outperform. (https://www.cnbc.com/) Fri. Nov 21, 2025 | |
| 19 (8) Abbott To Acquire Exact Sciences For About $23 Billion Abbott Laboratories (ABT) on Thursday said it has agreed to acquire Exact Sciences (EXAS) in a transaction worth an enterprise value of about $23 billion. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per share. (https://www.rttnews.com/) Thu. Nov 20, 2025 | |
| 20 (8) Solventum To Acquire Privately-held Acera Surgical For Up To $850 Mln Healthcare company Solventum Corp. (SOLV) announced Thursday it has entered into a definitive agreement to acquire Acera Surgical, a privately held bioscience company, for $725 million in cash plus up to $125 million in contingent cash payments based on the achievement of certain future milestones. (https://www.rttnews.com/) Thu. Nov 20, 2025 | |
| 21 (7) GE HealthCare To Buy Intelerad For $2.3 Bln GE HealthCare (GEHC) on Thursday said it has agreed to buy Intelerad, a medical imaging software provider for the healthcare industry, for a purchase price of $2. (https://www.rttnews.com/) Thu. Nov 20, 2025 | |
| 22 (8) GE HealthCare to Buy Intelerad for $2.3 Billion in Cash GE HealthCare Technologies Inc. is buying Intelerad Medical Systems Inc., a maker of medical imaging software, for $2.3 billion in cash to expand its efforts in cloud software and artificial intelligence. (https://www.bloomberg.com/) Thu. Nov 20, 2025 | |
| 23 (7) GE Healthcare to acquire Intelerad for $2.3 billion () -GE Healthcare said on Thursday it will acquire medical imaging software provider Intelerad for $2. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Leroy Leo). (https://finance.yahoo.com/) Thu. Nov 20, 2025 | |
| 24 (8) Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets. (https://www.benzinga.com/) Thu. Nov 20, 2025 | |
| 25 (3) Just Two Sectors Account for 100% of US Job Growth in 2025 If you’re looking for a job in health care or hospitality, the good news is US companies are hiring. But employers across the rest of the economy are scaling back. (https://www.bloomberg.com/) Thu. Nov 20, 2025 | |
| 26 (8) FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for advanced lung cancer. (https://www.benzinga.com/) Thu. Nov 20, 2025 | |
| 27 (5) Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences. (https://www.marketwatch.com/) Thu. Nov 20, 2025 | |
| 28 (7) Abbott’s $21 Billion Exact Sciences Deal Fills Void Of Lost Covid Test Sales Abbott Laboratories $21 billion deal to acquire cancer test maker Exact Sciences could bolster the company’s diagnostic division that has lost sales from COVID tests. (https://www.forbes.com/) Thu. Nov 20, 2025 | |
| 29 (8) Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics Abbott will acquire Exact Sciences for $21 billion, adding Cologuard and expanding its diagnostics portfolio as analysts highlight growth and valuation momentum. (https://www.benzinga.com/) Thu. Nov 20, 2025 | |
| 30 (8) FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio AstraZeneca receives FDA approval for Koselugo to treat adults with NF1 and inoperable plexiform neurofibromas, backed by strong Phase 3 data. (https://www.benzinga.com/) Thu. Nov 20, 2025 | |
| 31 (7) Abbott to Buy Cancer-Screener Exact Sciences for $21 Billion Abbott Laboratories agreed to acquire cancer-screening company Exact Sciences Corp., in a deal with a total equity value of about $21 billion. (https://www.bloomberg.com/) Thu. Nov 20, 2025 | |
| 32 (8) Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical device maker's diagnostics business. (https://www.cnbc.com/) Thu. Nov 20, 2025 | |
| 33 (7) Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences. (https://www.marketwatch.com/) Thu. Nov 20, 2025 | |
| 34 (-6) 133-year-old big pharma company plans layoffs, files WARN notice The global drugmaker is laying off workers as part of a restructuring. (https://www.thestreet.com/) Thu. Nov 20, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA